What are the challenges in targeting CDKs for cancer treatment?
Despite the potential of CDK inhibitors, several challenges remain. One major issue is the development of resistance to these drugs. Cancer cells can adapt by upregulating other cyclins or CDKs, or by activating alternative pathways that bypass the inhibited CDKs. Additionally, the toxicity of CDK inhibitors to normal proliferating cells can lead to adverse side effects, limiting their therapeutic window.
